Pfenex Inc. (PFNX) had a rough trading day for Wednesday March 06 as shares tumbled 7.61%, or a loss of $-0.35 per share, to close at $4.25. After opening the day at $4.63, shares of Pfenex Inc. traded as high as $4.63 and as low as $4.20. Volume was 105,203 shares over 805 trades, against an average daily volume of 77,992 shares and a total float of 31.46 million.
As a result of the decline, Pfenex Inc. now has a market cap of $133.71 million. In the last year, shares of Pfenex Inc. have traded between a range of $8.42 and $3.13, and its 50-day SMA is currently $3.90 and 200-day SMA is $4.74.
Pfenex is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. The vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.
Pfenex Inc. is based out of San Diego, CA and has some 65 employees. Its CEO is Evert B. Schimmelpennink.